Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.

ABSTRACT:

Background

Since the 1970s, CHOP chemotherapy has been the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL). In 2002, randomized trials changed this standard by showing that adding rituximab immunotherapy to CHOP improved survival. However, how these results influenced chemoimmunotherapy adoption in clinical practice remains unclear.

Methods

Using the National Cancer Database to compare chemoimmunotherapy use with chemotherapy alone, we collected data on demographics, stage, health insurance, area-level socioeconomic status (SES), facility characteristics, and type of treatment for DLBCL patients diagnosed in the United States 2001-2004. Multivariable log binomial models examined associations between race, insurance, and treatment allocation, adjust

SUBMITTER: Flowers CR 

PROVIDER: S-EPMC4155492 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature